In today’s Pharmaceutical Executive Daily, FDA approves Vybrique for erectile dysfunction, experts argue Phase III clinical ...

Veradermics Inc., a late clinical-stage biopharmaceutical company focused on hair restoration, raised $256.3 million in an ...

FDA has approved Vybrique, the first oral film formulation of sildenafil for the treatment of erectile dysfunction, offering ...

By giving small and mid-size biotechs access to real-world data and advanced analytics once reserved for large pharma, AI ...

After months of speculation, TrumpRx is live and offering Americans a variety of important medications at most-favored-nation prices. 1 Or, more accurately, it’s providing coupons for certain ...

In today’s Pharmaceutical Executive Daily, Susan G. Komen releases its 2026 breast cancer progress outlook, industry leaders ...

SanegeneBio and Genentech entered a global licensing agreement aimed at advancing an RNA interference (RNAi) therapeutic ...

In today’s Pharmaceutical Executive Daily, a new a is expected to evolve in 2026, the FDA rejects AstraZeneca’s application ...

Eli Lilly is investing $3.5 billion in a new manufacturing facility in Lehigh Valley, Pennsylvania, to produce injectable ...

PE: What was your experience debuting Trialynx at JP Morgan Healthcare 2026? Schwab: It’s fantastic. This was the culmination ...

Novo Nordisk’s 2026 outlook reflects this shift with an adjusted basis excluding the non-recurring reversal of $4.2 billion in 340B Drug Pricing Program rebate provisions. 1 Sales and operating profit ...

On February 1, FDA announced a new pilot program designed to promote the construction of domestic manufacturing sites, along ...